A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Pfizer13 enrolled

Overview

The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM). This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Transthyretin Amyloid Cardiomyopathy

Interventions

Tafamidis 61 milligramsDRUG

Tafamidis 61mg as provided in real-world practice

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥19 years * Patients diagnosed with ATTR-CM (ATTRwt and ATTRv) with tissue biopsy or nuclear scintigraphy * Patients who was prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once. Exclusion Criteria: * Presence of other amyloidosis

Locations (4)

Severance Hopital, Yonsei University Health System

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Samsung Medical Center

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Pusan National University Hospital

Busan, South Korea

Gangnam Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Number of Participants With Change From Baseline in New York Heart Association (NYHA) Classification